Additional studies need to analyze PTL in order to definitively accept it as an independent predictive biomarker for anti-EGFR therapy, especially as RCC and LCC are also characterized by different mutational landscapes. This evidence concerns the gene EGFR and leukoencephalopathy with calcifications and cysts.